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Decade of vaccinesVaccines are excellent investments with far-reaching rewards beyond individual and population health,
but their introduction into national programs has been historically slow in Africa. We provide an over-
view of the introduction of new and underutilized vaccines in countries of the WHO African Region by
2017, using data from the WHO-UNICEF Joint Reporting Form. By 2017, all 47 countries had introduced
vaccines containing hepatitis B (compared to 11% in 2000 and 98% in 2010) and Haemophilus influenzae
type b (Hib) (compared to 4% in 2000 and 91% in 2010). The proportion of countries that had introduced
other vaccines by 2017 was 83% for pneumococcal conjugate vaccine (PCV) from 7% in 2010, 72% for rota-
virus vaccine from 2% in 2010, 55% for the second dose of a measles-containing vaccine (MCV2) (com-
pared to 11% in 2000 and 17% in 2010), and 45% for rubella-containing vaccines (RCV) (compared to
4% in 2000 and 7% in 2010). From 2000 to 2010, there was no significant difference between countries
eligible (N = 36) and those not eligible (N = 10) for Gavi support in the introduction of hepatitis B and
PCV. However, Gavi eligible countries were more likely to introduce Hib and non-Gavi eligible countries
were more likely to introduce MCV2 and RCV. From 2010 to 2017, the only significant differences that
remained between the two groups of countries were with mumps, inactivated polio and seasonal influ-
enza vaccines; which non-Gavi eligible countries were more likely to have introduced. There has been
significant progress in the introduction of new childhood vaccines in Africa, mostly driven by Gavi sup-
port. As many countries are expected to transition out of Gavi support soon, there is need for countries in
the region to identify predictable, reliable and sustainable immunization funding mechanisms. This
requires commitments and actions that go beyond the purchase of vaccines.
 2019 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Immunization is one of the most cost-effective public health
interventions and remains one of the best buys in public health
[1,2]. An extensive investment in smallpox vaccine eradicated the
disease from the global scene at a cost of US$ 100 million over a
10-year period, between 1967 and 1977 [2]. Global savings from
smallpox eradication have exceeded US$ 1.3 billion a year in treat-
ment and prevention costs ever since [2]. Measles vaccination
between 2000 and 2016 prevented 20.4 million global deaths,making measles vaccine one of the greatest value investments
for public health [3]. While they have been progress towards elim-
ination of measles, the surge in measles outbreaks globally raises
concerns of pushing back the won gains. Overall, the 6 basic anti-
gens (bacille Calmette-Guerin, diphtheria, tetanus, pertussis, polio
and measles) originally recommended as childhood vaccines when
the Expanded Program on Immunization (EPI) was established in
1974 prevent more than two million child deaths each year [2].
By introducing and ensuring universal access to newer vaccines
(including, but not limited to those against hepatitis B, Hae-
mophilus influenzae type b (Hib), human papillomavirus, meningo-
coccus serogroup A, pneumococcal disease, and rotavirus), over 25
million future deaths could be averted between 2011 and 2020 and
billions of dollars in economic benefits could be generated by 2020
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been slow [5,6]. Since the establishment of the EPI in 1974, more
vaccines have been recommended for use in the childhood immu-
nization program, but there has been a very slow uptake of these in
the African region. Vaccines against hepatitis B and Hib took dec-
ades to be introduced in most African countries; after their intro-
ductions in high-income countries [6,7].
It is against this background that the Global Vaccine Action Plan
(GVAP) 2011–2020 was initiated, to provide universal access to life
saving vaccines [4]. The GVAP is a roadmap to achieve the vision of
the Decade of Vaccines i.e. ‘‘a world in which all individuals and
communities enjoy lives free of vaccine preventable diseases”.
The GVAP has five strategic goals, one of which is to develop and
introduce new and improved vaccines and technologies. One of
the targets for this strategic goal is for all low-income and
middle-income countries to introduce at least one new or
underutilized vaccine by 2020 [4]. As the Decade of Vaccines
(2011–2020) draws to a close, there is a need to evaluate the status
of the introduction of new vaccines in low and middle-income
countries. In this paper, we assessed the status of new vaccine
introduction in the World Health Organization (WHO) African
Region from 2010 to 2017 using the publicly available data from
the WHO/UNICEF Joint Reporting Form (JRF) [8].2. Method and analysis
We used data available in the WHO-UNICEF Joint Reporting
Form (JRF) as of 31 December 2017. The JRF contains immunization
data, including vaccine introductions, from all WHO Member
States worldwide [8]. Data in the JRF is collected using standard-
ized questionnaire completed by a national immunization author-
ity of a reporting country [8]. The deadline for which the data must
be completed is usually mid-April although countries may update
or amend previously reported data at any time with prior permis-
sion from WHO/UNICEF [8]. The last updated JRF was on 18
September 2018. All the data reported is reviewed for quality, com-
pleteness and consistency before publication on the WHO website
[8]. The data is categorical with countries responding ‘‘yes” if a vac-
cine is in the schedule and ‘‘no” if a vaccine is not in the schedule.
The vaccine introduction data in the excel sheet for each country
include the following variables: ‘‘vaccine in schedule”; ‘‘year of
introduction in the entire country” and ‘‘year of introduction in
part of the country”. We counted the number (and calculated the
proportion) of countries that had each vaccine in their national
schedule by 2000, 2010, and 2017. We used the chi-squared test
to assess the differences between proportions using the Stata Soft-
ware version 15.1. We defined statistical significance at the alphaTable 1
Comparison of vaccine introductions in Gavi and non-Gavi countries in Africa between 20





Hepatitis B 2 (6%) 36 (100%)
Haemophilus influenzae type b 1 (3%) 35 (97%)
Pneumococcal conjugate N/A 2 (6%)
Rotavirus N/A 0 (0%)
Measles second dose 1 (3%) 1 (3%)
Rubella 0 (0%) 1 (3%)
Human papillomavirus N/A) 0 (0%)
Mumps 0 (0%) 0 (0%)
Influenza 0 (0%) 0 (0%)
Inactivated polio vaccine 0 (0%) 0 (0%)
N refers to number of countries. Values provided are absolute counts (percentage), unles
included in the table because these are not recommended for all countries in the region
The p-value shows the Fisher exact test results for difference in introductions betweenlevel of 5%. We did not require a formal ethical review for this
study as the data are publicly available.3. Results
There were 46 countries in the WHO African Region from 2000
to 2010. With the independence of South Sudan in 2011, the num-
ber of countries went up to 47. Of the 47 countries, 37 (79%) were
eligible for support from Gavi, the Vaccine Alliance, and 10 (21%)
were not eligible. To be eligible for Gavi support, countries must
have a Gross National Income (GNI) per capita of US$ 1580 or
below on average over the past three years. Although Angola and
the Republic of Congo have transitioned out of Gavi support, we
considered the two countries as Gavi eligible for the purposes of
this paper because they received Gavi support to introduce the
vaccines considered in the paper. The 10 countries not eligible
for Gavi support (self-financing) for the whole study period from
2000 to 2017 include Algeria, Botswana, Cape Verde, Equatorial
Guinea, Gabon, Mauritius, Namibia, Seychelles, South Africa and
Swaziland.
Table 1 shows the status of introduction of new and underuti-
lized vaccines (NUVs) in WHO African countries between 2000
and 2010 while Table 2 shows the status of introduction between
2010 and 2017. Between 2000 and 2010, hepatitis B and Hib were
the most introduced underutilized vaccines to the basic six anti-
gens of the EPI. In 2010, an average of 3 of the 12 NUVs had been
introduced by most countries; this increased to an average of 7 of
the 12 NUVs introduced by most countries in 2017. The three most
frequently introduced NUVs were for hepatitis B, Hib and yellow
fever; and four vaccines introduced in 2017: PCV, rotavirus, IPV
or bivalent oral polio and second dose of measles containing vac-
cines. In 2010, self-financing countries introduced the most NUVs.
By 2010, Seychelles had introduced 7 NUVs while Mauritius and
South Africa had introduced 6 NUVs. The Gambia was the only Gavi
eligible country that had introduced 6 NUVs in 2010. In 2017, Sey-
chelles and Mauritius had 10 and 11 NUVs respectively. The intro-
duction of NUVs in Gambia and South Africa increased from 6 in
both countries to 9 in 2017.
In 2010, 45 of 47 countries reported to have introduced hepati-
tis B vaccine. By 2017 all the countries had introduced hepatitis B
vaccine with Equatorial Guinea and South Sudan introducing the
vaccine in 2013 and 2014 respectively. Of 47 countries administer-
ing hepatitis B vaccine in 2017, 37 were Gavi-eligible countries and
10 were self-financing countries. Hib vaccine was in the schedule
in 43 countries in 2010 and this increased to 47 by 2016. Botswana,
Equatorial Guinea, Nigeria and South Sudan are among countries
that introduced Hib vaccine after 2010. There were 35 Gavi eligible00 and 2010.





5 (50%) 9 (90%) 0.217
1 (10%) 8 (80%) 0.115
0 (0%) 1 (10%) 0.530
0 (0%) 1 (10%) –
4 (40%) 6 (60%) 0.000
1 (10%) 2 (20%) 0.115
0 (0%) 0 (0%) –
2 (20%) 3 (30%) 0.008
0 (0%) 0 (0%) –
0 (0%) 1 (10%) 0.217
s otherwise indicated. Yellow fever and meningococcal A conjugate vaccines are not
.
Gavi and self-financing countries by 2010.
Table 2
Comparison of vaccine introductions in Gavi and self-financing countries in Africa between 2010 and 2017.









Hepatitis B 36 (100%) 37 (100%) 9 (90%) 10 (100%) –
Haemophilus influenzae type b 35 (97%) 37 (100%) 8 (80%) 10 (100%) –
Pneumococcal conjugate 2 (6%) 33 (86%) 1 (10%) 6 (60%) 0.051
Rotavirus 0 (0%) 28 (76%) 1 (10%) 6 (60%) 0.272
Measles second dose 1 (3%) 18 (49%) 6 (60%) 8 (80%) 0.077
Rubella 1 (3%) 14 (38%) 2 (20%) 7 (70%) 0.073
Human papillomavirus 0 (0%) 3 (8%) 0 (0%) 4 (40%) 0.029
Mumps 0 (0%) 0 (0%) 3 (30%) 4 (40%) 0.001
Influenza 0 (0%) 0 (0%) 0 (0%) 4 (40%) 0.001
Inactivated polio vaccine 0 (0%) 27 (73%) 1 (10%) 10 (100%) 0.067
N refers to number of countries. Values provided are absolute counts (percentage), unless otherwise indicated. Yellow fever and meningococcal A conjugate vaccines are not
included in the table because these are not recommended for all countries in the region.
The p-value shows the Fisher exact test results for difference in introductions between Gavi and self-financing countries by 2017.
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this increased to 37 and 10, respectively in 2016.
In 2010, only 2 Gavi eligible countries (Gambia and Rwanda)
and one self-financing country (South Africa) had introduced pneu-
mococcal conjugate vaccine (PCV). This number increased to 39
countries in 2017. Six (6) of the 39 countries who had introduced
PCV were self-financing countries. Of those that introduced PCV
in 2017, Nigeria was the only country to partially introduce the
PCV vaccine with plans to roll-out to the entire country.
In 2010, 7 countries reported to have introduced measles-
containing-vaccine second-dose, this increased to 26 countries in
2017. Eighteen of these countries including South Sudan were Gavi
eligible and 8 were self-financing countries. There was an increase
in rubella vaccine introduction from 3 in 2010 to 21 in 2017. Sey-
chelles was the first country in Africa to have introduced rubella
vaccine in 1980 followed by Mauritius in 1996 and Cabo Verde
in 2010. There were 14 Gavi eligible and 7 self-financing countries
that introduced rubella vaccine in 2017.
There were 3 self-financing countries that had introduced
mumps vaccine by 2010, this increased to 4 self-financing coun-
tries in 2017. The first country in the WHO African region to intro-
duce mumps vaccine was Seychelles in 1998 followed by Mauritius
in 2000 and Cabo Verde in 2010. Algeria introduced mumps vac-
cine in 2017.
Among the 28 countries in the WHO African region identified
to be at risk of yellow fever (YF), only 23 risk countries had
introduced the yellow fever vaccine in 2017. Burundi, Ethiopia,
Mauritania, South Sudan and Uganda are classified as at risk,
but had not introduced YF vaccine as of 2017. Seychelles and
Sao Tome and Principe, although not identified at risk of YF,
had introduced the vaccine in 1995 and 2003 respectively mak-
ing total of 25 countries in the region that had introduced YF inTable 3
When vaccines first become licensed, first country to license and first pre-qualified by the
Antigen Year of First License
Hepatitis B 1986









Polio Vaccine – Inactivated 19552017. Equatorial Guinea was the only country to introduce the
YF vaccine in 2017. Of the 25 countries that had introduced YF
vaccine by 2017, three were self-financing countries (Equatorial
Guinea, Gabon and Seychelles). Kenya remains the only country
at a higher risk to YF in 2017 that has not introduced the vac-
cine in the entire country.
The region had a sharp increase in rotavirus vaccine introduc-
tion from one country in 2010 to 34 countries in 2017. Of the 34
countries to introduce the vaccine by 2017, 28 were Gavi eligible
countries and 6 were self-financing countries. South Africa was
the only self-financing country in the region to introduce rotavirus
vaccine by 2010, first launched in one district in 2008 followed by a
national roll out in 2009 (Table 1).
In 2017, 7 countries in the region had introduced human papil-
loma virus vaccine nationwide. Of these, four (Botswana, Mauri-
tius, Seychelles and South Africa) were self-financing countries.
None of the countries in the WHO African region had intro-
duced meningococcal vaccine (MenAfriVac) in 2010 as MenAfriVac
only was licensed for use in 2010. Six Gavi supported countries,
including Burkina Faso, Central African Republic, Chad, Ghana, Mali
and Niger had introduced meningococcal vaccine by 2017.
Four (4) self-financing countries, Algeria, South Africa, Mauri-
tius and Swaziland had introduced seasonal influenza vaccine by
2017. None of the countries in the region had introduced seasonal
influenza vaccine in 2010.
Only South Africa had introduced inactivated polio vaccine
(IPV) in 2010, in 2017 37 countries had introduced the vaccine.
The majority of countries in the region to introduce IPV were Gavi
eligible (27 countries) compared to self-financing countries (10
countries). Countries that are still to introduce IPV by 2017 include
Burkina Faso, Eritrea, Ghana, Malawi, Rwanda, Sierra Leone, Togo,
United Republic of Tanzania, Zambia and Zimbabwe.WHO.
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more likely to introduce the NUVs. We found no significant statis-
tical relationship (p > 0.05) to conclude that Gavi eligible countries
were more likely to introduce the 10 vaccines introduced between
2010 and 2017. The introduction of three vaccines in this period;
mumps (p < 0.001), human papilloma virus vaccine (p = 0.029)
and seasonal influenza (p < 0.001) were strongly associated with
non-Gavi support (Table 2). In Table 1, between 2000 and 2010,
mumps (p < 0.008) and MCV2 (p < 0.000) were strongly associated
with self-financing countries. The list of vaccines when first
become licensed and pre-qualified are shown in Table 3. A com-
plete list of the vaccines when it was prequalified by the WHO
can be found on the WHO website https://extranet.who.int/gavi/
PQ_Web/.4. Discussion
The aim of the study was to examine the progress made in the
introduction of new and underutilized vaccines (NUVs) between
2000 and 2017 in the WHO African region. We found significant
progress in the introduction of NUVs across the WHO African
region (Tables 1 and 2). An average of 7 NUVs were introduced
in the African region by 2017 compared to 3 in 2010. One of goals
of the Decade of Vaccines (DoV) 2011–2020 is to ensure that all
low and middle-income countries introduce one or more appropri-
ate NUVs by 2020 [4]. That goal has since been achieved although
coverage needs to be raised for these vaccines.
By 2017, all countries had introduced hepatitis B and haemo-
philus influenzae type b (Hib) vaccines thereby demonstrating that
the introduction of NUVs in the WHO African region is achievable.
While this is a measure of success, it took 17–20 years for all coun-
tries in the WHO African region to introduce, two highly effective
low-cost vaccines, hepatitis B and Hib. Compared to well-
developed countries, this is a lag period of over 30 years for many
countries, between the time the vaccine such as hepatitis B and Hib
was introduced in a developed country to the time it was intro-
duced to some of these countries. More recently, there has been
a significant increase in the introduction of vaccines such as pneu-
mococcal conjugate vaccine (39 of 47), rotavirus (34 of 47),
measles-containing-vaccine second-dose vaccine (MCV2) (26 of
47) and rubella (21 of 47) after its first introduction in the global
north. Gavi has made this significant achievement possible through
its support to eligible countries (37 of 47). Gavi has also gone into
supporting immunization systems within countries, including
planning which has had the impact of improved coverage and
has aimed at sustainability of the immunization programs and
the gains of new vaccines introduction. In addition to Gavi support,
Men-Afri-Vac has been possible to be introduced in many coun-
tries due to a successful public-private partnerships with vaccine
manufacturing companies. In case of rotavirus, international not-
for-profit organization and other immunization partners funded
by Bill and Melinda has been key in providing technical assistance
thus increasing access to and effectiveness of existing commercial
rotavirus vaccines worldwide. The acceleration in the introduction
of IPV and bivalent OPV is part of the Polio Eradication and End-
game Strategic Plan 2013–2018, that requires eventual cessation
of all the 3 types’ oral polio vaccine [9]. Therefore, the Polio Erad-
ication Initiative has been working with countries to introduce IPV
and to switch trivalent to bivalent OPV.
When we assessed the relationship of the increase in the NUVs
introduction between Gavi and self-financing countries we found
no significant differences in the introduction of many of the NUVs.
The likely explanation is that all countries (Gavi eligible or not)
supported the accelerated introduction of NUVs and assumed
responsibility for their immunization programs. It could also bethat self-financing countries (10 of 47), many of which have are
small and have a higher GNI per capita are able to finance the
new introduction of vaccines including financing vaccines that
are not universally recommended in the EPI such as mumps and
influenza.
This does not suggest that in the coming years, low and middle-
income countries scheduled to transition from Gavi support due to
a raised GDP per capita will fund their immunization programs
successfully with own money. There are other additional core
issues besides financing of new vaccines after Gavi ceases support
to poor countries. Although graduating countries may fully fund
the purchase of vaccines, however, in the absence of good procure-
ment practices and functional regulatory system, transitioning will
be hard to achieve. The introduction of new vaccines overwhelms
the vaccine supply chains; subsequently immunization coverage
drops and this hinders further introduction of new vaccines. In
the past, shortages have affected the supply of yellow fever, pneu-
mococcal, rotavirus, polio and HPV vaccines due to manufacturing
issues that caused delays and disruption to the routine and non-
routine immunization programmes. For example, due to shortages
and insufficient stockpiles, vaccines can be diverted away from the
routine immunization services to outbreak responses. To meet
goals of the DoV and GVAP, countries are expected to show com-
mitment towards immunization and ensure financial sustainability
of immunization programs: by raising their funds from national
budgets; establishing legal framework that guarantee adequate
domestic financing and procurement; and resource mobilization
from development partners to meet funding gaps.
According to the Gavi annual progress report for 2015, Ghana
and Sudan, for example, only funded 18% and 13% of total immu-
nization expenditures, respectively [10]. The demonstrated budget
commitment for middle-income countries like Ghana that is
expected to transition from Gavi support, and Malawi that does
not pay for any of their traditional vaccines raises doubts if these
countries will be financially independent and ready to extend
immunization and new vaccines to their targeted population after
exit from Gavi support [10]. These scenarios raise serious concerns
to whether low income countries will be able to mobilize their
resources, ensure financial sustainability and take full responsibil-
ity of their programs in the foreseeable future.
As many countries transition out of Gavi support, there is need
for collaborative partnerships between countries to work together
towards purchasing affordable vaccines to maintain and further
extend coverage. Collaboration is also needed between countries
to explore possibilities for the development of vaccines in the
region to reduce costs. With only two current vaccine manufactur-
ers in Africa (South Africa and Senegal), investment in regional vac-
cine production will also greatly reduce the time to introduction of
new vaccines. Most importantly it will guarantee supply security,
control over production scheduling, control of costs, contribute to
socio-economic development, and ensure rapid response to local
epidemics and sustainability [11]. Countries receiving Gavi subsi-
dies may be phased out soon need to plan and identify predictable
local funding sources. The revolving fund, created in 1979 by PAHO
for Member States is a highly impressive example that has yielded
success in national immunization programs throughout the PAHO
Region [12]. Some countries have established trust funds or used
dedicated tax revenues, among other strategies to fund their
immunization programs [4]. These initiatives are required in Africa
especially now that the introduction of NUVs such as mumps, HPV,
meningococcus, seasonal influenza, second dose of measles con-
taining vaccines must be stepped up in the region.
Strengthening of the performance of the health system is essen-
tial to additional progress and sustaining the any gains made. A
strong health system is a vehicle to facilitate successful introduc-
tion of NUVs and improved immunization coverage. Where exist-
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tion of NUVs can place a hefty burden on several critical functions
and this may weaken the whole health system proving to be a set-
back [13]. NUVs affect vaccine delivery and logistics as they
become widely administered. They not only increase the number
of vaccines and antigens covered by the immunization program
but the increase also comes from the volume of these new vaccines
which are often presented as single dose and prefilled syringes.
Zaffran and colleagues estimated that for countries introducing
pneumococcal conjugate vaccine and rotavirus vaccine the volume
increase is 143% per dose, with a serious effect on cold chain capac-
ity and the supply chain [14]. Furthermore, with increase in cold
chain storage capacity is the corresponding increase in transport
requirements. Haidari and colleagues, raises this point and laments
the limited focus on cold chain capacity requirements by WHO and
donors that does not consider and plan for additional transport
requirements when planning for new vaccine introduction [15].
While introduction of NUVs presents challenges, it also creates
extraordinary opportunities for enhancing routine immunization
programs by implementing many of the required reforms. NUVs
provides an entry point that pave way for scaling up and accelerat-
ing health care performance [16]. NUVs facilitate the widespread
use of auto-disable syringes into immunization and the broader
health systems [17]. In instances where an addition of a new vac-
cine does not correspond to the timing of the other doses in the
schedule, the new vaccine means an additional visit to health facil-
ities and thus provide an opportunity for additional health system
contact for catch up immunization for eligible populations who
previously missed vaccines. NUVs have reduced the incidence
and prevalence rates of targeted diseases. For example, human
rotavirus vaccine significantly reduced the incidence of severe
rotavirus gastroenteritis by 30.2% among African infants in two
countries during the first year of life [18]. In Rwanda, acute gas-
troenteritis admissions fell by 45–49% of all admissions among
children below 5 years following the introduction of rotavirus vac-
cine in 2012 [19]. Ghana’s introduction of pneumococcal and rota-
virus vaccines at the same time in 2012 although costly (US$ 3.2
million per year) was expected to prevent about 20% of the coun-
try’s under-five child mortality due to pneumonia and diarrhea
[20]. A study in Kenya assessing the impact of Hib vaccine intro-
duced in 2001, reduced the incidence of the disease from 626
per 100000 in 2001 to 45 per 100000 in 2004–14 [21].
This study has limitations. The JRF is self-reported data com-
pleted by country immunization authorities of WHO Member
States and we were unable to validate beyond the data published
by WHO. It would be beneficial if the JRF data in future is verified
by third parties in order to increase confidence in the data report-
ing system. We deliberately excluded other WHO regions in the
analysis of the JRF data thus we did not compare howWHO African
region performed at the global level and could not draw lessons on
introduction of NUVs from other WHO regions. This work will be
explored separately.5. Conclusion
While notable progress has been made by many countries in the
WHO African region and this is commendable, NUVs introduction
remains largely dependent on Gavi support. Self-financing coun-
tries such as South Africa, Seychelles and others are making com-
mendable progress in maintaining the introduction of NUVs.
Their financing models should be shared with other countries for
them to learn and plan ahead. The largest barrier to introduction
of NUVs remains the cost of vaccines and current dependence of
most African countries on Gavi support. Without funding for NUVs,
countries would not be able to pay for the purchase of NUVs. Thuslong-term financing of NUVs is much needed and countries must
begin to devote to planning and preparations related to funding
mechanism and sustainability. Countries migrating from Gavi to
self-financing need concerted efforts to ensure a step-wise pro-
gressive transfer of ownership of the whole immunization pro-
grams to local governments to ensure that systems and finances
are not just committed on paper. As many countries transition
out of Gavi funding in 2020, it is important for these countries to
maintain their existing immunization programs and continue to
introduce new vaccines driven by the disease burden of their pop-
ulations. There is need for political and administrative endorse-
ment of immunization policies and support systems that ensures
commitment and sustainability. There is also a need for countries
in the region to look into pooled funding mechanism and local
development of vaccines that will help ensure sustainable immu-
nization programs for future generations in Africa.
Declaration of Competing Interest
The authors declare that they have no competing interests.
Funding
This research did not receive any specific grant from funding
agencies in the public, commercial, or not-for-profit sectors.
Author contributions
Analyzed the data: EZS. Interpretation of the data: EZS, ABW,
NN, SM, CSW. Wrote the first draft of the manuscript: EZS. Con-
tributed to writing of the manuscript: EZS, ABW, NN, SM, CSW.
ICMJE criteria for authorship read and met: EZS, ABW, SM, NN,
CSW. Agree with manuscript results and conclusions; EZS, ABW,
SM, NN, CSW.
References
[1] Ozawa S, Clark S, Portnoy A, Grewal S, Brenzel L, Walker DG. Return on
investment from childhood immunization in low-and middle-income
countries, 2011–20. Health Aff 2016;35(2):199–207. https://doi.org/10.1377/
hlthaff.2015.1086.
[2] WHO, UNICEF, World Bank. State of the world’s vaccines and immunization.
3rd ed. Geneva: World Health Organization; 2009.
[3] World Health Organization. Measles, http://www.who.int/news-room/fact-
sheets/detail/measles/; 2018 [accessed 10 August 2018].
[4] Global Vaccine Action Plan 2011-2020, http://www.who.int/
immunization/global_vaccine_action_plan/GVAP_doc_2011_2020/en/; 2013
[accessed 10 August 2018].
[5] Mihigo R, Anya B, Okeibunor J, Ajibola S, Boakye-Agyemang C, Muzenda L, et al.
African vaccination week as a vehicle for integrated health service delivery.
BMC Health Serv Res 2015;15(1):358.
[6] Machingaidze S, Wiysonge CS, Hussey GD. Strengthening the expanded
program on immunization in Africa: looking beyond 2015. PLoS Med
2013;10(3):e1001405.
[7] Loharikar A, Dumolard L, Chu S, Hyde T, Goodman T, Mantel C. Status of New
Vaccine Introduction — Worldwide, September 2016. MMWR Morb Mortal
Wkly Rep 2016;65:1136–40. https://doi.org/10.15585/mmwr.mm6541a.
[8] WHO/UNICEF Joint Reporting Process, http://www.who.int/
immunization/monitoring_surveillance/routine/reporting/reporting/en/
[accessed 10 August 2018].
[9] Global Polio Eradication Initiative. Polio Eradication and Endgame Strategic
Plan 2013-2018, http://polioeradication.org/wp-content/uploads/2016/07/
PEESP_EN_A4.pdf [accessed 22 February 2019].
[10] Gavi Alliance Secretariat. Report of the new proposal independent review
committee to the Gavi Alliance Secretariat on the review of applications.
World Health Organization; 2015.
[11] Plotkin S, Robinson JM, Cunningham G, Iqbal R, Larsen S. The complexity and
cost of vaccine manufacturing–an overview. Vaccine 2017;35(33):4064–71.
[12] Andrus JK, Bandyopadhyay AS, Danovaro-Holliday M, Dietz V, Domingues C,
Figueroa JP, et al. The past, present, and future of immunization in the
Americas. Rev Panam Salud Publica 2018;41:. https://doi.org/10.26633/
RPSP.2017.121e121.
[13] Hyde TB, Dentz H, Wang SA, Burchett HE, Mounier-Jack S, Mantel CF, et al. The
impact of new vaccine introduction on immunization and health systems: a
E.Z. Sambala et al. / Vaccine 37 (2019) 3290–3295 3295review of the published literature. Vaccine 2012;30(45):6347–58. https://doi.
org/10.1016/j.vaccine.2012.08.029.
[14] Zaffran M, Vandelaer J, Kristensen D, Melgaard B, Yadav P, Antwi-Agyei K, et al.
The imperative for stronger vaccine supply and logistics systems. Vaccine
2013;31:B73–80. https://doi.org/10.1016/j.vaccine.2012.11.036.
[15] Haidari LA, Connor DL, Wateska AR, Brown ST, Mueller LE, Norman BA, et al.
Augmenting transport versus increasing cold storage to improve vaccine
supply chains. PLoS ONE 2013;8(5):. https://doi.org/10.1371/journal.
pone.0064303e64303.
[16] Lahariya C. ‘‘Health system approach” for improving immunization program
performance. J Family Med Prim Care 2015;4(4):487–94. https://doi.org/
10.4103/2249-4863.174263.
[17] World Health Organization. Principles and considerations for adding a vaccine
to a national immunization program: from decision to implementation and
monitoring, http://apps.who.int/iris/bitstream/handle/10665/111548/
9789241506892?sequence=1; 2014 [accessed 10 August 2018].[18] Madhi SA, Cunliffe NA, Steele D, Witte D, Kirsten M, Louw C, et al. Effect of
human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med
2010;362(4):289–98. https://doi.org/10.1056/NEJMoa0904797.
[19] Mihigo R, Okeibunor J, Anya B, Mkanda P, Zawaira F. Challenges of
immunization in the African Region. Pan Afr Med J 2017;27(Suppl 3).
https://doi.org/10.11604/pamj.supp.2017.27.3.12127.
[20] Gavi Alliance. Ghana rolls out vaccines against two top killers of children:
Simultaneous introduction is first in African history, http://www.who.int/
pmnch/media/news/2012/20120426_gavipressrelease.pdf; 2012 [accessed 13
March 2019].
[21] Hammitt LL, Crane RJ, Karani A, Mutuku A, Morpeth SC, Burbidge P, et al. Effect
of Haemophilus influenzae type b vaccination without a booster dose on
invasive H influenzae type b disease, nasopharyngeal carriage, and population
immunity in Kilifi, Kenya: a 15-year regional surveillance study. Lancet Glob
Health 2016;4(3):e185–94. https://doi.org/10.1016/S2214-109X(15)00316-2.
